See the published version of this preprint at Stem Cell Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Dezhi Tang
longhua hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction Osthole has a potential therapeutic application for anti-osteoporosis. The present study verified whether osthole downregulates osteoclastogenesis via targeting OPG.
Methods In vivo, 12-month-old male mice were utilized to evaluate the effect of osthole on bone mass. In vitro, bone marrow stem cells (BMSCs) were isolated and extracted from 3-month-old OPG-/- mice and the littermates of OPG+/+ mice. calvaria osteoblasts were extracted from 3-day-old C57BL/6J mice or 3-day-old OPG-/- mice and the littermates of OPG+/+ mice.
Results Osthole significantly increased the gene and protein levels of OPG in primary BMSCs in a dose-dependent manner. The deletion of the OPG gene did not affect β-catenin expression. The deletion of the β-catenin gene inhibited OPG expression in BMSCs, indicating that osthole stimulates the expression of OPG via activation of β-catenin signaling.
Conclusion Osthole attenuates osteoclast formation by stimulating the activation of β-catenin-OPG signaling and could be a potential drug for the senile osteoporosis.
Keywords
Osthole, β-catenin, Osteoprotegerin, Osteoclast, Osteoporosis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Stem Cell Research & Therapy.
Version 2
Posted 26 Jan, 2021
No community comments so far
Editorial decision: Major Revision
On 27 Jan, 2021
Review #2 received
Received 26 Jan, 2021
Review #1 received
Received 23 Jan, 2021
Reviewer #2 agreed
On 20 Jan, 2021
Reviewer #1 agreed
On 20 Jan, 2021
Editor assigned
On 19 Jan, 2021
Reviewers invited
Invitations sent on 19 Jan, 2021
Submission checks complete
On 19 Jan, 2021
Editor invited
On 19 Jan, 2021
No comments provided
Editorial decision: Major Revision
On 03 Jan, 2021
Review #3 received
Received 02 Jan, 2021
Reviewer #2 agreed
On 21 Dec, 2020
Reviewer #3 agreed
On 21 Dec, 2020
Reviewer #4 agreed
On 21 Dec, 2020
Reviewer #1 agreed
On 21 Dec, 2020
Review #1 received
Received 21 Dec, 2020
Review #2 received
Received 21 Dec, 2020
Editor assigned
On 20 Dec, 2020
Reviewers invited
Invitations sent on 20 Dec, 2020
Submission checks complete
On 20 Dec, 2020
Editor invited
On 20 Dec, 2020
First submitted
On 16 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Stem Cell Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Dezhi Tang
longhua hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Stem Cell Research & Therapy.
Version 2
Posted 26 Jan, 2021
No community comments so far
Editorial decision: Major Revision
On 27 Jan, 2021
Review #2 received
Received 26 Jan, 2021
Review #1 received
Received 23 Jan, 2021
Reviewer #2 agreed
On 20 Jan, 2021
Reviewer #1 agreed
On 20 Jan, 2021
Editor assigned
On 19 Jan, 2021
Reviewers invited
Invitations sent on 19 Jan, 2021
Submission checks complete
On 19 Jan, 2021
Editor invited
On 19 Jan, 2021
No comments provided
Editorial decision: Major Revision
On 03 Jan, 2021
Review #3 received
Received 02 Jan, 2021
Reviewer #2 agreed
On 21 Dec, 2020
Reviewer #3 agreed
On 21 Dec, 2020
Reviewer #4 agreed
On 21 Dec, 2020
Reviewer #1 agreed
On 21 Dec, 2020
Review #1 received
Received 21 Dec, 2020
Review #2 received
Received 21 Dec, 2020
Editor assigned
On 20 Dec, 2020
Reviewers invited
Invitations sent on 20 Dec, 2020
Submission checks complete
On 20 Dec, 2020
Editor invited
On 20 Dec, 2020
First submitted
On 16 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Stem Cell Research & Therapy.
Introduction Osthole has a potential therapeutic application for anti-osteoporosis. The present study verified whether osthole downregulates osteoclastogenesis via targeting OPG.
Methods In vivo, 12-month-old male mice were utilized to evaluate the effect of osthole on bone mass. In vitro, bone marrow stem cells (BMSCs) were isolated and extracted from 3-month-old OPG-/- mice and the littermates of OPG+/+ mice. calvaria osteoblasts were extracted from 3-day-old C57BL/6J mice or 3-day-old OPG-/- mice and the littermates of OPG+/+ mice.
Results Osthole significantly increased the gene and protein levels of OPG in primary BMSCs in a dose-dependent manner. The deletion of the OPG gene did not affect β-catenin expression. The deletion of the β-catenin gene inhibited OPG expression in BMSCs, indicating that osthole stimulates the expression of OPG via activation of β-catenin signaling.
Conclusion Osthole attenuates osteoclast formation by stimulating the activation of β-catenin-OPG signaling and could be a potential drug for the senile osteoporosis.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...